The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Esther Nkemakolam runs her fingers through kinetic sand and sings a “Moana” song as UPMC Children’s Hospital nurse Taylor ...

There is huge unmet need for new rare disease therapies, where patients have few or no available options. According to the ...

Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the next ...

The biotech's Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed with Vertex Pharmaceuticals, is now approved in the U.S ...

This latest gene therapy offering is Casgevy, which treats sickle cell disease and transfusion-dependent beta thalassemia, a blood disorder that reduces the production of hemoglobin.

Casgevy, which carries a $2.2 million list price, won FDA approval in December 2023 to treat sickle cell disease, and a month later received agency authorization to treat transfusion-dependent ...

The FDA approval and launch of CASGEVY, a gene therapy for treating sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) in patients 12 years and older, have created ...

Pope Francis remains in critical condition and “is not out of danger,” the Holy See Press Office announced Saturday evening in Rome. The 88-year-old pontiff “experienced an asthma-like ...

But the voucher was never granted by the U.S. regulator despite providing one for Vertex and CRISPR Therapeutics’ development of their sickle cell disease gene therapy Casgevy. With the pricing ...